請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65500
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 顧記華 | |
dc.contributor.author | Jui-Ling Hsu | en |
dc.contributor.author | 徐瑞苓 | zh_TW |
dc.date.accessioned | 2021-06-16T23:46:49Z | - |
dc.date.available | 2017-09-19 | |
dc.date.copyright | 2012-09-19 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-07-23 | |
dc.identifier.citation | 1. Choi, J.H. & Lee, K.T. Costunolide-induced apoptosis in human leukemia cells: involvement of c-jun N-terminal kinase activation. Biol Pharm Bull 32, 1803-1808 (2009).
2. Nam, N.H. Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem 6, 945-951 (2006). 3. Kanno, S., Kitajima, Y., Kakuta, M., Osanai, Y., Kurauchi, K., Ujibe, M. & Ishikawa, M. Costunolide-induced apoptosis is caused by receptor-mediated pathway and inhibition of telomerase activity in NALM-6 cells. Biol Pharm Bull 31, 1024-1028 (2008). 4. Bocca, C., Gabriel, L., Bozzo, F. & Miglietta, A. A sesquiterpene lactone, costunolide, interacts with microtubule protein and inhibits the growth of MCF-7 cells. Chem Biol Interact 147, 79-86 (2004). 5. Lin, T.H., Chang, S.J., Chen, C.C., Wang, J.P. & Tsao, L.T. Two phenanthraquinones from Dendrobium moniliforme. J Nat Prod 64, 1084-1086 (2001). 6. Elmore, S. Apoptosis: a review of programmed cell death. Toxicol Pathol 35, 495-516 (2007). 7. Sinkovics, J.G. Programmed cell death (apoptosis): its virological and immunological connections (a review). Acta Microbiol Hung 38, 321-334 (1991). 8. Munoz-Pinedo, C. Signaling pathways that regulate life and cell death: evolution of apoptosis in the context of self-defense. Adv Exp Med Biol 738, 124-143 (2012). 9. Alenzi, F.Q., Lotfy, M. & Wyse, R. Swords of cell death: caspase activation and regulation. Asian Pac J Cancer Prev 11, 271-280 (2010). 10. D'Autreaux, B. & Toledano, M.B. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 8, 813-824 (2007). 11. Franco, R. & Cidlowski, J.A. Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ 16, 1303-1314 (2009). 12. Kim, S.J., Jung, H.J. & Lim, C.J. Disruption of redox homeostasis and induction of apoptosis by suppression of glutathione synthetase expression in a mammalian cell line. Free Radic Res 45, 1040-1051 (2011). 13. Franco, R. & Cidlowski, J.A. Glutathione Efflux and Cell Death. Antioxid Redox Signal (2012). 14. Laborde, E. Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. Cell Death Differ 17, 1373-1380 (2010). 15. Hall, A.G. Review: The role of glutathione in the regulation of apoptosis. Eur J Clin Invest 29, 238-245 (1999). 16. Anathy, V., Aesif, S.W., Guala, A.S., Havermans, M., Reynaert, N.L., Ho, Y.S., Budd, R.C. & Janssen-Heininger, Y.M. Redox amplification of apoptosis by caspase-dependent cleavage of glutaredoxin 1 and S-glutathionylation of Fas. J Cell Biol 184, 241-252 (2009). 17. Berridge, M.J., Bootman, M.D. & Lipp, P. Calcium--a life and death signal. Nature 395, 645-648 (1998). 18. Flourakis, M. & Prevarskaya, N. Insights into Ca2+ homeostasis of advanced prostate cancer cells. Biochim Biophys Acta 1793, 1105-1109 (2009). 19. Monteith, G.R., McAndrew, D., Faddy, H.M. & Roberts-Thomson, S.J. Calcium and cancer: targeting Ca2+ transport. Nat Rev Cancer 7, 519-530 (2007). 20. Wasilenko, W.J., Cooper, J., Palad, A.J., Somers, K.D., Blackmore, P.F., Rhim, J.S., Wright, G.L., Jr. & Schellhammer, P.F. Calcium signaling in prostate cancer cells: evidence for multiple receptors and enhanced sensitivity to bombesin/GRP. Prostate 30, 167-173 (1997). 21. Bunn, P.A., Jr., Dienhart, D.G., Chan, D., Puck, T.T., Tagawa, M., Jewett, P.B. & Braunschweiger, E. Neuropeptide stimulation of calcium flux in human lung cancer cells: delineation of alternative pathways. Proc Natl Acad Sci U S A 87, 2162-2166 (1990). 22. Xiao, D., Qu, X. & Weber, H.C. Activation of extracellular signal-regulated kinase mediates bombesin-induced mitogenic responses in prostate cancer cells. Cell Signal 15, 945-953 (2003). 23. Bootman, M.D., Fearnley, C., Smyrnias, I., MacDonald, F. & Roderick, H.L. An update on nuclear calcium signalling. J Cell Sci 122, 2337-2350 (2009). 24. Rodrigues, M.A., Gomes, D.A., Leite, M.F., Grant, W., Zhang, L., Lam, W., Cheng, Y.C., Bennett, A.M. & Nathanson, M.H. Nucleoplasmic calcium is required for cell proliferation. J Biol Chem 282, 17061-17068 (2007). 25. Tomida, T., Hirose, K., Takizawa, A., Shibasaki, F. & Iino, M. NFAT functions as a working memory of Ca2+ signals in decoding Ca2+ oscillation. EMBO J 22, 3825-3832 (2003). 26. Khodarev, N.N. & Ashwell, J.D. An inducible lymphocyte nuclear Ca2+/Mg(2+)-dependent endonuclease associated with apoptosis. J Immunol 156, 922-931 (1996). 27. Fang, M., Zhang, H., Xue, S., Li, N. & Wang, L. Intracellular calcium distribution in apoptosis of HL-60 cells induced by harringtonine: intranuclear accumulation and regionalization. Cancer Lett 127, 113-121 (1998). 28. Anderson, K.M., Rubenstein, M., Alrefai, W.A., Dudeja, P., Tsui, P. & Harris, J.E. Acute changes in U937 nuclear Ca2+ preceding type 1 'apoptotic' programmed cell death due to MK 886. Anticancer Res 24, 2601-2615 (2004). 29. Dypbukt, J.M., Thor, H. & Nicotera, P. Intracellular Ca2+ chelators prevent DNA damage and protect hepatoma 1C1C7 cells from quinone-induced cell killing. Free Radic Res Commun 8, 347-354 (1990). 30. Poljakova, J., Eckschlager, T., Hrabeta, J., Hrebackova, J., Smutny, S., Frei, E., Martinek, V., Kizek, R. & Stiborova, M. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem Pharmacol 77, 1466-1479 (2009). 31. Guay, D., Garand, C., Reddy, S., Schmutte, C. & Lebel, M. The human endonuclease III enzyme is a relevant target to potentiate cisplatin cytotoxicity in Y-box-binding protein-1 overexpressing tumor cells. Cancer Sci 99, 762-769 (2008). 32. Tanaka, T., Huang, X., Halicka, H.D., Zhao, H., Traganos, F., Albino, A.P., Dai, W. & Darzynkiewicz, Z. Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents. Cytometry A 71, 648-661 (2007). 33. Vermeulen, K., Van Bockstaele, D.R. & Berneman, Z.N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36, 131-149 (2003). 34. Murray, A.W. Recycling the cell cycle: cyclins revisited. Cell 116, 221-234 (2004). 35. Schwartz, G.K. & Shah, M.A. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23, 9408-9421 (2005). 36. Abbas, T. & Dutta, A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9, 400-414 (2009). 37. Basile, V., Ferrari, E., Lazzari, S., Belluti, S., Pignedoli, F. & Imbriano, C. Curcumin derivatives: molecular basis of their anti-cancer activity. Biochem Pharmacol 78, 1305-1315 (2009). 38. Dirks, P.B. & Rutka, J.T. Current concepts in neuro-oncology: the cell cycle--a review. Neurosurgery 40, 1000-1013; discussion 1013-1005 (1997). 39. Carcagno, A.L., Ogara, M.F., Sonzogni, S.V., Marazita, M.C., Sirkin, P.F., Ceruti, J.M. & Canepa, E.T. E2F1 transcription is induced by genotoxic stress through ATM/ATR activation. IUBMB Life 61, 537-543 (2009). 40. Liu, Z., Liu, Q., Xu, B., Wu, J., Guo, C., Zhu, F., Yang, Q., Gao, G., Gong, Y. & Shao, C. Berberine induces p53-dependent cell cycle arrest and apoptosis of human osteosarcoma cells by inflicting DNA damage. Mutat Res 662, 75-83 (2009). 41. Ball, H.L., Myers, J.S. & Cortez, D. ATRIP binding to replication protein A-single-stranded DNA promotes ATR-ATRIP localization but is dispensable for Chk1 phosphorylation. Mol Biol Cell 16, 2372-2381 (2005). 42. Rogakou, E.P., Pilch, D.R., Orr, A.H., Ivanova, V.S. & Bonner, W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273, 5858-5868 (1998). 43. Obrador, E., Carretero, J., Pellicer, J.A. & Estrela, J.M. Possible mechanisms for tumour cell sensitivity to TNF-alpha and potential therapeutic applications. Curr Pharm Biotechnol 2, 119-130 (2001). 44. Zhang, S., Ong, C.N. & Shen, H.M. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett 208, 143-153 (2004). 45. Choi, S.H., Im, E., Kang, H.K., Lee, J.H., Kwak, H.S., Bae, Y.T., Park, H.J. & Kim, N.D. Inhibitory effects of costunolide on the telomerase activity in human breast carcinoma cells. Cancer Lett 227, 153-162 (2005). 46. Honda, T., Coppola, S., Ghibelli, L., Cho, S.H., Kagawa, S., Spurgers, K.B., Brisbay, S.M., Roth, J.A., Meyn, R.E., Fang, B. & McDonnell, T.J. GSH depletion enhances adenoviral bax-induced apoptosis in lung cancer cells. Cancer Gene Ther 11, 249-255 (2004). 47. Estrela, J.M., Ortega, A. & Obrador, E. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43, 143-181 (2006). 48. Macho, A., Hirsch, T., Marzo, I., Marchetti, P., Dallaporta, B., Susin, S.A., Zamzami, N. & Kroemer, G. Glutathione depletion is an early and calcium elevation is a late event of thymocyte apoptosis. J Immunol 158, 4612-4619 (1997). 49. van den Dobbelsteen, D.J., Nobel, C.S., Schlegel, J., Cotgreave, I.A., Orrenius, S. & Slater, A.F. Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/APO-1 antibody. J Biol Chem 271, 15420-15427 (1996). 50. You, B.R., Kim, S.Z., Kim, S.H. & Park, W.H. Gallic acid-induced lung cancer cell death is accompanied by ROS increase and glutathione depletion. Mol Cell Biochem 357, 295-303 (2011). 51. Matsumaru, K., Ji, C. & Kaplowitz, N. Mechanisms for sensitization to TNF-induced apoptosis by acute glutathione depletion in murine hepatocytes. Hepatology 37, 1425-1434 (2003). 52. Olas, B. & Wachowicz, B. Inhibitory effects of cisplatin and its conjugate with glutathione on blood platelet activity. Platelets 9, 69-72 (1998). 53. Blair, I.A. Endogenous glutathione adducts. Curr Drug Metab 7, 853-872 (2006). 54. Drew, R. & Miners, J.O. The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation. Biochem Pharmacol 33, 2989-2994 (1984). 55. Ballatori, N., Krance, S.M., Marchan, R. & Hammond, C.L. Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. Mol Aspects Med 30, 13-28 (2009). 56. Paolicchi, A., Dominici, S., Pieri, L., Maellaro, E. & Pompella, A. Glutathione catabolism as a signaling mechanism. Biochem Pharmacol 64, 1027-1035 (2002). 57. Jurma, O.P., Hom, D.G. & Andersen, J.K. Decreased glutathione results in calcium-mediated cell death in PC12. Free Radic Biol Med 23, 1055-1066 (1997). 58. Gomez, L.D., Noctor, G., Knight, M.R. & Foyer, C.H. Regulation of calcium signalling and gene expression by glutathione. J Exp Bot 55, 1851-1859 (2004). 59. Bartlett, J.D., Luethy, J.D., Carlson, S.G., Sollott, S.J. & Holbrook, N.J. Calcium ionophore A23187 induces expression of the growth arrest and DNA damage inducible CCAAT/enhancer-binding protein (C/EBP)-related gene, gadd153. Ca2+ increases transcriptional activity and mRNA stability. J Biol Chem 267, 20465-20470 (1992). 60. Salas, V.M. & Corcoran, G.B. Calcium-dependent DNA damage and adenosine 3',5'-cyclic monophosphate-independent glycogen phosphorylase activation in an in vitro model of acetaminophen-induced liver injury. Hepatology 25, 1432-1438 (1997). 61. Popescu, R., Heiss, E.H., Ferk, F., Peschel, A., Knasmueller, S., Dirsch, V.M., Krupitza, G. & Kopp, B. Ikarugamycin induces DNA damage, intracellular calcium increase, p38 MAP kinase activation and apoptosis in HL-60 human promyelocytic leukemia cells. Mutat Res 709-710, 60-66 (2011). 62. Papa, S., Bubici, C., Zazzeroni, F., Pham, C.G., Kuntzen, C., Knabb, J.R., Dean, K. & Franzoso, G. The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ 13, 712-729 (2006). 63. Schoonbroodt, S. & Piette, J. Oxidative stress interference with the nuclear factor-kappa B activation pathways. Biochem Pharmacol 60, 1075-1083 (2000). 64. Estevez, L.G. & Gradishar, W.J. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 10, 3249-3261 (2004). 65. Jackson, J.R., Patrick, D.R., Dar, M.M. & Huang, P.S. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 7, 107-117 (2007). 66. Rouleau, M., Patel, A., Hendzel, M.J., Kaufmann, S.H. & Poirier, G.G. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10, 293-301 (2010). 67. Chang, P., Jacobson, M.K. & Mitchison, T.J. Poly(ADP-ribose) is required for spindle assembly and structure. Nature 432, 645-649 (2004). 68. Landino, L.M., Moynihan, K.L., Todd, J.V. & Kennett, K.L. Modulation of the redox state of tubulin by the glutathione/glutaredoxin reductase system. Biochem Biophys Res Commun 314, 555-560 (2004). 69. Huang, Q., Lu, G., Shen, H.M., Chung, M.C. & Ong, C.N. Anti-cancer properties of anthraquinones from rhubarb. Med Res Rev 27, 609-630 (2007). 70. Alves, D.S., Perez-Fons, L., Estepa, A. & Micol, V. Membrane-related effects underlying the biological activity of the anthraquinones emodin and barbaloin. Biochem Pharmacol 68, 549-561 (2004). 71. van Dalen, E.C., van der Pal, H.J., Bakker, P.J., Caron, H.N. & Kremer, L.C. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur J Cancer 40, 643-652 (2004). 72. Hamzehloo, A. & Etemadifar, M. Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis. Arch Iran Med 9, 111-114 (2006). 73. Bellosillo, B., Colomer, D., Pons, G. & Gil, J. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 100, 142-146 (1998). 74. Ramachandran, C., Samy, T.S., Huang, X.L., Yuan, Z.K. & Krishan, A. Doxorubicin-induced DNA breaks, topoisomerase II activity and gene expression in human melanoma cells. Biochem Pharmacol 45, 1367-1371 (1993). 75. Huang, H.S., Chen, T.C., Chen, R.H., Huang, K.F., Huang, F.C., Jhan, J.R., Chen, C.L., Lee, C.C., Lo, Y. & Lin, J.J. Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,11-dione homologues. Bioorg Med Chem 17, 7418-7428 (2009). 76. Collier, D.A. & Neidle, S. Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones. J Med Chem 31, 847-857 (1988). 77. Huang, H.S., Chiu, H.F., Lee, A.L., Guo, C.L. & Yuan, C.L. Synthesis and structure-activity correlations of the cytotoxic bifunctional 1,4-diamidoanthraquinone derivatives. Bioorg Med Chem 12, 6163-6170 (2004). 78. Huang, H.S., Huang, K.F., Li, C.L., Huang, Y.Y., Chiang, Y.H., Huang, F.C. & Lin, J.J. Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem 16, 6976-6986 (2008). 79. Huang, H.S., Chou, C.L., Guo, C.L., Yuan, C.L., Lu, Y.C., Shieh, F.Y. & Lin, J.J. Human telomerase inhibition and cytotoxicity of regioisomeric disubstituted amidoanthraquinones and aminoanthraquinones. Bioorg Med Chem 13, 1435-1444 (2005). 80. Huang, H.S., Huang, K.F., Lee, C.C., Chen, C.L., Li, C.L. & Lin, J.J. NSC746364, NSC746365, and NSC746366: the spectra of cytotoxicity and molecular correlates of response to telomerase activity. Anticancer Drugs 21, 169-180 (2010). 81. Lee, C.C., Huang, K.F., Lin, P.Y., Huang, F.C., Chen, C.L., Chen, T.C., Guh, J.H., Lin, J.J. & Huang, H.S. Synthesis, antiproliferative activities and telomerase inhibition evaluation of novel asymmetrical 1,2-disubstituted amidoanthraquinone derivatives. Eur J Med Chem 47, 323-336 (2012). 82. Gangloff, Y.G., Mueller, M., Dann, S.G., Svoboda, P., Sticker, M., Spetz, J.F., Um, S.H., Brown, E.J., Cereghini, S., Thomas, G. & Kozma, S.C. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol 24, 9508-9516 (2004). 83. Murakami, M., Ichisaka, T., Maeda, M., Oshiro, N., Hara, K., Edenhofer, F., Kiyama, H., Yonezawa, K. & Yamanaka, S. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol 24, 6710-6718 (2004). 84. Zoncu, R., Efeyan, A. & Sabatini, D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12, 21-35 (2011). 85. Vignot, S., Faivre, S., Aguirre, D. & Raymond, E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16, 525-537 (2005). 86. Wang, C., Gao, D., Guo, K., Kang, X., Jiang, K., Sun, C., Li, Y., Sun, L., Shu, H., Jin, G., Sun, H., Wu, W. & Liu, Y. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model. BMC Cancer 12, 166 (2012). 87. Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J. & Yonezawa, K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177-189 (2002). 88. Sarbassov, D.D., Ali, S.M., Kim, D.H., Guertin, D.A., Latek, R.R., Erdjument-Bromage, H., Tempst, P. & Sabatini, D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14, 1296-1302 (2004). 89. Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Ruegg, M.A., Hall, A. & Hall, M.N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6, 1122-1128 (2004). 90. Facchinetti, V., Ouyang, W., Wei, H., Soto, N., Lazorchak, A., Gould, C., Lowry, C., Newton, A.C., Mao, Y., Miao, R.Q., Sessa, W.C., Qin, J., Zhang, P., Su, B. & Jacinto, E. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 27, 1932-1943 (2008). 91. Garcia-Martinez, J.M. & Alessi, D.R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416, 375-385 (2008). 92. Yip, C.K., Murata, K., Walz, T., Sabatini, D.M. & Kang, S.A. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell 38, 768-774 (2010). 93. De Benedetti, A. & Harris, A.L. eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 31, 59-72 (1999). 94. Graff, J.R., Konicek, B.W., Carter, J.H. & Marcusson, E.G. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68, 631-634 (2008). 95. Mayer, C., Zhao, J., Yuan, X. & Grummt, I. mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev 18, 423-434 (2004). 96. Shackelford, D.B. & Shaw, R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9, 563-575 (2009). 97. Hemminki, A., Markie, D., Tomlinson, I., Avizienyte, E., Roth, S., Loukola, A., Bignell, G., Warren, W., Aminoff, M., Hoglund, P., Jarvinen, H., Kristo, P., Pelin, K., Ridanpaa, M., Salovaara, R., Toro, T., Bodmer, W., Olschwang, S., Olsen, A.S., Stratton, M.R., de la Chapelle, A. & Aaltonen, L.A. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391, 184-187 (1998). 98. Wingo, S.N., Gallardo, T.D., Akbay, E.A., Liang, M.C., Contreras, C.M., Boren, T., Shimamura, T., Miller, D.S., Sharpless, N.E., Bardeesy, N., Kwiatkowski, D.J., Schorge, J.O., Wong, K.K. & Castrillon, D.H. Somatic LKB1 mutations promote cervical cancer progression. PLoS One 4, e5137 (2009). 99. Ji, H., Ramsey, M.R., Hayes, D.N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M.C., Shimamura, T., Perera, S.A., Liang, M.C., Cai, D., Naumov, G.N., Bao, L., Contreras, C.M., Li, D., Chen, L., Krishnamurthy, J., Koivunen, J., Chirieac, L.R., Padera, R.F., Bronson, R.T., Lindeman, N.I., Christiani, D.C., Lin, X., Shapiro, G.I., Janne, P.A., Johnson, B.E., Meyerson, M., Kwiatkowski, D.J., Castrillon, D.H., Bardeesy, N., Sharpless, N.E. & Wong, K.K. LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807-810 (2007). 100. Jimenez, A.I., Fernandez, P., Dominguez, O., Dopazo, A. & Sanchez-Cespedes, M. Growth and molecular profile of lung cancer cells expressing ectopic LKB1: down-regulation of the phosphatidylinositol 3'-phosphate kinase/PTEN pathway. Cancer Res 63, 1382-1388 (2003). 101. Boudeau, J., Baas, A.F., Deak, M., Morrice, N.A., Kieloch, A., Schutkowski, M., Prescott, A.R., Clevers, H.C. & Alessi, D.R. MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J 22, 5102-5114 (2003). 102. Shaw, R.J., Kosmatka, M., Bardeesy, N., Hurley, R.L., Witters, L.A., DePinho, R.A. & Cantley, L.C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 101, 3329-3335 (2004). 103. Song, P., Xie, Z., Wu, Y., Xu, J., Dong, Y. & Zou, M.H. Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells. J Biol Chem 283, 12446-12455 (2008). 104. Lizcano, J.M., Goransson, O., Toth, R., Deak, M., Morrice, N.A., Boudeau, J., Hawley, S.A., Udd, L., Makela, T.P., Hardie, D.G. & Alessi, D.R. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23, 833-843 (2004). 105. Chen, A.Y. & Liu, L.F. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34, 191-218 (1994). 106. Eder, J.P., Chan, V., Wong, J., Wong, Y.W., Ara, G., Northey, D., Rizvi, N. & Teicher, B.A. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother Pharmacol 42, 327-335 (1998). 107. Saraiya, B., Gounder, M., Dutta, J., Saleem, A., Collazo, C., Zimmerman, L., Nazar, A., Gharibo, M., Schaar, D., Lin, Y., Shih, W., Aisner, J., Strair, R.K. & Rubin, E.H. Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anticancer Drugs 19, 411-420 (2008). 108. McMenamin, M.E., Soung, P., Perera, S., Kaplan, I., Loda, M. & Sellers, W.R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59, 4291-4296 (1999). 109. Kremer, C.L., Klein, R.R., Mendelson, J., Browne, W., Samadzedeh, L.K., Vanpatten, K., Highstrom, L., Pestano, G.A. & Nagle, R.B. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66, 1203-1212 (2006). 110. Morgan, T.M., Koreckij, T.D. & Corey, E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 9, 237-249 (2009). 111. Niedzwiecka, A., Marcotrigiano, J., Stepinski, J., Jankowska-Anyszka, M., Wyslouch-Cieszynska, A., Dadlez, M., Gingras, A.C., Mak, P., Darzynkiewicz, E., Sonenberg, N., Burley, S.K. & Stolarski, R. Biophysical studies of eIF4E cap-binding protein: recognition of mRNA 5' cap structure and synthetic fragments of eIF4G and 4E-BP1 proteins. J Mol Biol 319, 615-635 (2002). 112. Slepenkov, S.V., Darzynkiewicz, E. & Rhoads, R.E. Stopped-flow kinetic analysis of eIF4E and phosphorylated eIF4E binding to cap analogs and capped oligoribonucleotides: evidence for a one-step binding mechanism. J Biol Chem 281, 14927-14938 (2006). 113. Puli, S., Jain, A., Lai, J.C. & Bhushan, A. Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells. Neurochem Res 35, 986-993 (2010). 114. Wang, X., Yue, P., Chan, C.B., Ye, K., Ueda, T., Watanabe-Fukunaga, R., Fukunaga, R., Fu, H., Khuri, F.R. & Sun, S.Y. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol 27, 7405-7413 (2007). 115. Olanich, M.E., Moss, B.L., Piwnica-Worms, D., Townsend, R.R. & Weber, J.D. Identification of FUSE-binding protein 1 as a regulatory mRNA-binding protein that represses nucleophosmin translation. Oncogene 30, 77-86 (2011). 116. Inoki, K., Zhu, T. & Guan, K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590 (2003). 117. Cheng, S.W., Fryer, L.G., Carling, D. & Shepherd, P.R. Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J Biol Chem 279, 15719-15722 (2004). 118. Gwinn, D.M., Shackelford, D.B., Egan, D.F., Mihaylova, M.M., Mery, A., Vasquez, D.S., Turk, B.E. & Shaw, R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30, 214-226 (2008). 119. Xie, Z., Dong, Y., Scholz, R., Neumann, D. & Zou, M.H. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 117, 952-962 (2008). 120. Stavridi, F., Karapanagiotou, E.M. & Syrigos, K.N. Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev 36, 122-130 (2010). 121. Di Lorenzo, G., Autorino, R., Figg, W.D. & De Placido, S. Hormone-refractory prostate cancer: where are we going? Drugs 67, 1109-1124 (2007). 122. Reyland, M.E. Protein kinase C isoforms: Multi-functional regulators of cell life and death. Front Biosci 14, 2386-2399 (2009). 123. Brodie, C. & Blumberg, P.M. Regulation of cell apoptosis by protein kinase c delta. Apoptosis 8, 19-27 (2003). 124. Kim, E.H., Kim, S.U. & Choi, K.S. Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 24, 838-849 (2005). 125. Tillman, D.M., Izeradjene, K., Szucs, K.S., Douglas, L. & Houghton, J.A. Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res 63, 5118-5125 (2003). 126. Lim, J.H., Park, J.W., Kim, S.H., Choi, Y.H., Choi, K.S. & Kwon, T.K. Rottlerin induces pro-apoptotic endoplasmic reticulum stress through the protein kinase C-delta-independent pathway in human colon cancer cells. Apoptosis 13, 1378-1385 (2008). 127. Lim, J.H., Park, J.W., Choi, K.S., Park, Y.B. & Kwon, T.K. Rottlerin induces apoptosis via death receptor 5 (DR5) upregulation through CHOP-dependent and PKC delta-independent mechanism in human malignant tumor cells. Carcinogenesis 30, 729-736 (2009). 128. Li, Q.Y., Zu, Y.G., Shi, R.Z. & Yao, L.P. Review camptothecin: current perspectives. Curr Med Chem 13, 2021-2039 (2006). 129. Teicher, B.A. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 75, 1262-1271 (2008). 130. Avemann, K., Knippers, R., Koller, T. & Sogo, J.M. Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mol Cell Biol 8, 3026-3034 (1988). 131. Pommier, Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 109, 2894-2902 (2009). 132. Antony, S., Jayaraman, M., Laco, G., Kohlhagen, G., Kohn, K.W., Cushman, M. & Pommier, Y. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Cancer Res 63, 7428-7435 (2003). 133. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6, 789-802 (2006). 134. Reese, D.M., Tchekmedyian, S., Chapman, Y., Prager, D. & Rosen, P.J. A phase II trial of irinotecan in hormone-refractory prostate cancer. Invest New Drugs 16, 353-359 (1998). 135. Jane, E.P., Premkumar, D.R. & Pollack, I.F. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther 319, 1070-1080 (2006). 136. Kurosu, T., Tsuji, K., Kida, A., Koyama, T., Yamamoto, M. & Miura, O. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta. Oncogene 26, 2975-2987 (2007). 137. Zhang, J., Liu, N., Liu, S., Liu, Y. & Zheng, D. PKCdelta protects human breast tumor MCF-7 cells against tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis. J Cell Biochem 96, 522-532 (2005). 138. Cory, S. & Adams, J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2, 647-656 (2002). 139. Youle, R.J. & Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9, 47-59 (2008). 140. Lee, H.Z. Protein kinase C involvement in aloe-emodin- and emodin-induced apoptosis in lung carcinoma cell. Br J Pharmacol 134, 1093-1103 (2001). 141. Flores-Rozas, H., Kelman, Z., Dean, F.B., Pan, Z.Q., Harper, J.W., Elledge, S.J., O'Donnell, M. & Hurwitz, J. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc Natl Acad Sci U S A 91, 8655-8659 (1994). 142. Koike, M., Yutoku, Y. & Koike, A. Accumulation of p21 proteins at DNA damage sites independent of p53 and core NHEJ factors following irradiation. Biochem Biophys Res Commun 412, 39-43 (2011). 143. Condorelli, F., Salomoni, P., Cotteret, S., Cesi, V., Srinivasula, S.M., Alnemri, E.S. & Calabretta, B. Caspase cleavage enhances the apoptosis-inducing effects of BAD. Mol Cell Biol 21, 3025-3036 (2001). 144. Gschwendt, M., Muller, H.J., Kielbassa, K., Zang, R., Kittstein, W., Rincke, G. & Marks, F. Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 199, 93-98 (1994). 145. Soltoff, S.P. Rottlerin: an inappropriate and ineffective inhibitor of PKCdelta. Trends Pharmacol Sci 28, 453-458 (2007). 146. Bjornsti, M.A., Benedetti, P., Viglianti, G.A. & Wang, J.C. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 49, 6318-6323 (1989). 147. Riches, L.C., Lynch, A.M. & Gooderham, N.J. Early events in the mammalian response to DNA double-strand breaks. Mutagenesis 23, 331-339 (2008). 148. Smith, J., Tho, L.M., Xu, N. & Gillespie, D.A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 108, 73-112 (2010). 149. Kiselev, E., DeGuire, S., Morrell, A., Agama, K., Dexheimer, T.S., Pommier, Y. & Cushman, M. 7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents. J Med Chem 54, 6106-6116 (2011). 150. You, Q.D., Li, Z.Y., Huang, C.H., Yang, Q., Wang, X.J., Guo, Q.L., Chen, X.G., He, X.G., Li, T.K. & Chern, J.W. Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification. J Med Chem 52, 5649-5661 (2009). 151. Gongora, C., Vezzio-Vie, N., Tuduri, S., Denis, V., Causse, A., Auzanneau, C., Collod-Beroud, G., Coquelle, A., Pasero, P., Pourquier, P., Martineau, P. & Del Rio, M. New Topoisomerase I mutations are associated with resistance to camptothecin. Mol Cancer 10, 64 (2011). 152. Malik, M. & Nitiss, J.L. DNA repair functions that control sensitivity to topoisomerase-targeting drugs. Eukaryot Cell 3, 82-90 (2004). 153. Capranico, G., Marinello, J. & Baranello, L. Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: implications for physiological and therapeutic modulation of enzyme activity. Biochim Biophys Acta 1806, 240-250 (2010). 154. Baranello, L., Bertozzi, D., Fogli, M.V., Pommier, Y. & Capranico, G. DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerase II from promoter-prox | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65500 | - |
dc.description.abstract | 前列腺癌是男性罹患癌症致死的主因之一。目前前列腺癌的治療策略仍局限於手術、化學治療、冷凍切片、荷爾蒙治療及放射線治療。其中,對於荷爾蒙療法無效的荷爾蒙不依賴型前列腺癌仍是臨床治療上的一大困境。由於治療荷爾蒙不依賴型前列腺癌相當棘手,因此尋求有效的治療方式可說是備受矚目。在本篇論文中,將針對荷爾蒙不依賴型前列腺癌提出治療策略。第一部分與第二部分將著重於探討多種天然物及化學合成化合物的抗癌機轉,第三部分則是首次提出rottlerin與camptothecin合併療法的研究。
本論文的第一部分,我們將探討天然物costunolide及moniliformediquinone的抗癌機轉,且將著重於探討氧化性壓力、鈣離子失衡及DNA損傷的角色。Costunolide的結構為倍半萜內酯(sesquiterpene lactone),本實驗室欲探討新的機轉來強調其對荷爾蒙不依賴型前列腺癌細胞具有抗癌效果,並使用多種實驗方法來釐清其抗癌作用機轉。首先使用SRB方法(sulforhodamine B assay)、clonogenic test、流式細胞儀及carboxyfluorescein succinimidyl ester (CFSE)染色來確定costunolide在荷爾蒙依賴型前列腺癌LNCaP細胞株及荷爾蒙不依賴型PC-3、DU145細胞株抑制生長的情況。接著發現costunolide在PC-3細胞株能快速造成細胞核中鈣離子上升,並引發DNA損傷與ATR磷酸化。同時造成細胞週期G1期停滯、p21蛋白表現增加、p21/cdk2/cyclinE複合物結合增加以及Rb蛋白去磷酸化。這些現象可被鈣離子螯合劑BAPTA-AM與抗氧化劑glutathione (GSH)及其前驅物N-acetylcysteine (NAC)所抑制,然而另一種抗氧化劑trolox卻無效。這表示調控細胞內鈣離子及thiol含量減少對於細胞凋亡的重要性,來達到抗前列腺癌的效果,而活性氧化物的角色較不重要。以上實驗結果顯示,costunolide會造成細胞內thiol含量減少及細胞核內鈣離子上升,造成DNA損傷及p21表現量增加,p21經由與cdk2/cyclin E複合物結合,而抑制cdk2的活性與Rb蛋白的磷酸化,最後造成細胞週期停留於G1期及細胞凋亡。 Moniliformediquinone屬於phenanthraquinone結構的化合物,是由石斛得到的天然物。其在高度轉移性荷爾蒙不依賴型前列腺癌細胞株PC-3中,展現抗細胞生長及促進細胞凋亡的能力。本研究中,使用了多種方法來釐清moniliformediquinone在PC-3細胞的抗癌機轉。細胞在moniliformediquinone的處理下, 分別使用monochlorobimane (mClB)及fluo-3-AM染劑偵測GSH及鈣離子,發現會快速地造成細胞內GSH含量下降以及細胞質內鈣離子濃度上升。此外,moniliformediquinone也會迅速引起DNA損傷反應,並且造成相關蛋白 ATM、CHK1、CHK2和RPA32的磷酸化。接著,moniliformediquinone會引起粒線體壓力,造成粒線體膜電位的下降、Mcl-1蛋白(Bcl-2家族蛋白中抗細胞凋亡蛋白)的斷裂以及cytochrome c由粒線體釋放到細胞質中。而且,經由偵測IκB-α的磷酸化與降解以及NF-κB冷光試驗,結果皆顯示moniliformediquinone會活化NF-κB。另外值得注意的是,由in vivo 微小管試驗中,處理moniliformediquinone也會造成微小管不穩定。若預先給予sulfhydryl化合物GSH及NAC,可完全抑制moniliformediquinone造成的細胞反應,顯示了細胞內GSH含量對moniliformediquinone抗癌機轉的重要性。由以上實驗結果得知,moniliformediquinone會造成細胞內GSH含量下降,使細胞內鈣離子濃度上升、引起 DNA 損傷反應與粒線體喪失功能,最後導致PC-3細胞的生長抑制及細胞凋亡。 第二部分將探討化學合成anthraquinone衍生物EJMC30的抗癌機轉。EJMC30對於PC-3及H9c2心肌母細胞株具有良好的選擇性,GI50的值分別為8.64及大於30 μM。細胞處理EJMC30會造成細胞週期停滯於G1期,伴隨著細胞週期調控蛋白cyclin D1與cyclin E的表現量減少,以及p21蛋白的表現量增加。EJMC30也經由抑制mTOR (Ser2448)、4E-BP1 (Thr37/Thr46/Thr70)與 p70S6K (Thr389)的磷酸化,造成mTOR主導的轉譯途徑受到抑制。進一步分析ribosomal profiling後發現EJMC30會抑制蛋白生成轉譯途徑的起始及延長階段。接著EJMC30能快速導致mTOR上游蛋白Liver kinase B1 (LKB1)- 5'-AMP-activated protein kinase (AMPK)途徑的活化,顯示LKB1-AMPK途徑對於EJMC30作用機轉的重要性。總結來說,EJMC30 會經由LKB1-AMPK-mTOR途徑而影響ribosomal profiling及蛋白質轉譯,導致細胞週期停滯於G1期而抑制癌細胞生長。 然而,對化學治療藥物產生抗藥性仍是前列腺癌進展過程的主要機轉之一。因此,針對藥物機轉研發化學治療藥物,找尋新方法來增強細胞死亡可視為治療前列腺癌的策略之一。合併療法即是對抗荷爾蒙不依賴型前列腺癌的方法,可增強藥物的細胞毒殺效果與減少抗藥性的產生。在本論文的第三部分,我們提出了合併使用rottlerin與camptothecin的可能性。Rottlerin為含多酚結構的天然物,本研究發現其與topoisomerase I inhibitor camptothecin對於荷爾蒙不依賴型前列腺癌細胞株PC-3的毒殺作用有協同作用。雖然rottlerin為已知的protein kinase C-δ (PKC-δ) 抑制劑,但使用siRNA技術降低PKC-δ 的表現量,結果顯示rottlerin造成的協同作用與PKC-δ無關。Rottlerin能增強camptothecin在S期引起的DNA斷裂以及ATM蛋白在Ser1981的磷酸化程度,且 ATM的磷酸化程度與細胞凋亡呈現正相關 (r2 = 0.9)。接著偵測更上游的訊號,camptothecin的作用能穩定topoisomerase與DNA的複合物,導致形成結合camptothecin的topoisomerase I-DNA斷裂複合物,而合併rottlerin能增加複合物的形成。接著為了偵測對DNA修復能力的影響,檢測了短暫處理camptothecin並移除後,γH2A.X在不同時間點的變化。結果顯示,camptothecin移除後γH2A.X在S期的表現量會隨時間而逐漸減少,但合併rottlerin會抑制此現象,表示rottlerin存在下會抑制DNA修復的能力。並且,合併處理camptothecin與rottlerin時會造成Bax構型的變化而活化Bax,同時形成Bad蛋白的降解,表示粒線體壓力對於細胞凋亡的貢獻。總結來說,rottlerin 增強camptothecin的細胞毒殺能力來自於增加TOP1cc的穩定而導致增強DNA損傷壓力,以及可能抑制了DNA修復的能力。接著,經由活化Bax及造成Bad的裂解而造成粒線體壓力且引發細胞凋亡。此研究的嶄新發現提供了rottlerin與camptothecin合併療法用於荷爾蒙不依賴型前列腺癌的可能性。 | zh_TW |
dc.description.abstract | Prostate cancer is a major cause of cancer mortality in males. Prostate cancer treatment options are now limited to surgery, chemotherapy, cryotherapy, hormonal therapy, and radiation. Hormone-refractory prostate cancer (HRPC), resistant to hormone therapy, is a major obstacle in clinical treatment. Owning to the intractable treatment of HRPC, the development of efficient approaches is highly demanded. In this thesis, we have identified the mechniasms of several nature products and synthetic compounds against HRPC on the part-I and part-II. We provided a cancer therapeutic strategy of combinatory use between rottlerin and camptothecin for the effective treatment of HRPC on the part-III.
On the Part-I, we have identified the anti-cancer mechanism of natural products, costunolide and moniliformediquinone. The roles of oxidative stress, calcium imbalance and DNA damage were focused on this part. Several pharmacological and biochemical assays were used to characterize the apoptotic signaling pathways of costunolide, a natural sesquiterpene lactone, in prostate cancer cells. Costunolide showed effective antiproliferative activity against hormone dependent (LNCaP) and independent (PC-3 and DU-145) prostate cancer cells by sulforhodamine B assay, clonogenic test and flow cytometric analysis of carboxyfluorescein succinimidyl ester labeling. The data showed that costunolide induced a rapid overload of nuclear Ca2+, DNA damage response and ATR phosphorylation in PC-3 cells. Costunolide induced G1-phase cell cycle arrest, which was supported by p21 up-regulation and its association with the cyclin dependent kinase 2/cyclin E complex. The association resulted in inhibition of the complex activity and inhibition of Rb phosphorylation. Costunolide mediated effects were substantially inhibited by glutathione, the reactive oxygen species scavenger and glutathione precursor N-acetylcysteine, and the Ca2+ chelator BAPTA-AM other than the reactive oxygen species scavenger Trolox. This indicated the crucial role of intracellular Ca2+ mobilization and thiol depletion but not of reactive oxygen species production in apoptotic signaling. Data suggest that costunolide induces the depletion of intracellular thiols and overload of nuclear Ca2+ that cause DNA damage and p21 up-regulation. The association of p21 with the cyclin dependent kinase 2/cyclin E complex blocks cyclin dependent kinase 2 activity and inhibits Rb phosphorylation, leading to G1 arrest of the cell cycle and subsequent apoptotic cell death in human prostate cancer cells. Moniliformediquinone, a nature phenanthraquinone compound obtained from Dendrobium moniliforme, displayed antiproliferative and apoptotic activity in PC-3 cells, a highly metastatic HRPC. In the present work, several approaches were used to clarify the anticancer mechanism of Moniliformediquinone in PC-3 cells. Moniliformediquinone treatment rapidly caused the depletion of the intracellular glutathione (GSH) and an increase of cytosolic calcium concentration by using mClB and fluo-3-AM staining, respectively. Furthermore, Moniliformediquinone promptly induced DNA damage response (DDR) and phosphorylation of DDR-related protein, such as ATM, CHK1, CHK2 and RPA32. The mitochondrial stress was subsequently induced by Moniliformediquinone through the identification of the loss of mitochondrial membrane potential (ΔΨm), cleavage of Mcl-1 (an anti-apoptotic Bcl-2 family member) and the release of cytochrome c from mitochondria to cytosol. Moreover, the data by the detection of phosphorylation and degradation of IκB-α and NF-κB luciferase assay showed that NF-κB was markedly activated. Of note, cytoskeleton instability was observed after Moniliformediquinone treatment by in vivo tubulin assay. Pretreatment with sulfhydryl compounds, GSH and N-acetylcysteine (NAC), completely blocked the Moniliformediquinone-mediated cellular effect, highlighting the critical role of the intracellular GSH level to Moniliformediquinone action. Taken together, the data suggest that Moniliformediquinone may deplete intracellular GSH content which, in turn, causes an increase of cytosolic calcium level and induce DNA damage response and mitochondrial dysfunction, leading to antiproliferative effect and apoptosis in PC-3 cells. On the Part-II, we have identified the anti-cancer mechanism of an anthraquinone derivative, EJMC30. EJMC30 presented a remarkable selectivity between PC-3 and H9c2 cardiomyoblasts with GI50 values of 8.64 and more than 30 μM, respectiviely. EJMC30 treatment caused G1 arrest of cell cyle associated with down-regulation of cell cycle related proteins, such as cyclinD1 and cyclin E, and up-regulattion of p21 expression. EJMC30 also inhibited mTOR-dependent translational pathways through inhibition of mTOR (Ser2448), 4E-BP1 (Thr37/Thr46/Thr70) and p70S6K (Thr389). Further analysis showed that EJCM30 inhibited the initiation and elongation of protein translation by ribosomal profiling analysis. Moreover, EJMC30 quickly induced the activation of LKB1-AMPK, the upstream kinase of mTOR pathway, suggesting the central role of LKB1-AMPK to EJMC30 action. Taken together, the data suggest EJMC30 affects ribosomal profiling and protein translation that may be through LKB1-AMPK-mTOR dependent pathway, leading to G1 arrest of the cell cycle and growth inhibition. However, resistance to chemotherapeutic agents is a major mechanism in prostate cancer progression. With the mechanism-based development of chemotherapy, discovery of new approaches to enhance cell death signals may be an attractive strategy in prostate cancer treatment. Combination therapy, which can optimize killing activity to cancers and minimize drug resistance, is a mainstream therapy against HRPCs. On the Part-III, we provided an anticancer strategy of combinatory use between rottlerin and camptothecin. Rottlerin, a natural polyphenolic component, synergistically increased PC-3 apoptosis induced by camptothecin (a topoisomerase I inhibitor). Using siRNA technique to knockdown protein kinase C-δ (PKC-δ), the data showed that rottlerin-mediated synergistic effect was PKC-δ-independent, although rottlerin has been used as a PKC-δ inhibitor. Rottlerin potentiated camptothecin-induced DNA fragmentation at S phase and ATM phosphorylation at Ser1981. The effect was correlated to apoptosis (r2 = 0.9). To detect upstream signals, the data showed that camptothecin acted on and stabilized topoisomerase I-DNA complex, leading to the formation of camptothecin-trapped cleavage complexes. The effect was potentiated by rottlerin. To determine DNA repair capability, the time-related γH2A.X formation was examined after camptothecin removal. Consequently, rottlerin significantly inhibited camptothecin removal-mediated decline of γH2A.X formation at S phase, indicating the impairment of DNA repair activity in the presence of rottlerin. The combinatory treatment of camptothecin and rottlerin induced conformational change and activation of Bax and formation of truncated Bad, suggesting the contribution of mitochondria stress to apoptosis. In summary, the data suggest that rottlerin-mediated camptothecin sensitization is through the augmented stabilization of topoisomerase I-DNA cleavage complex (TOP1cc), leading to an increase of DNA damage stress and, possibly, an impairment of DNA repair capability. Subsequently, mitochondria-involved apoptosis is triggered through Bax activation and truncated Bad formation. The novel discovery may provide an anticancer approach of combinatory use between rottlerin and camptothecin for the treatment of HRPCs. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T23:46:49Z (GMT). No. of bitstreams: 1 ntu-101-D97423004-1.pdf: 5621115 bytes, checksum: d68594857be25000e5127f6bf579441d (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 縮寫表…………….…………………………………………………………………...1
中文摘要………………………………………………………………………………2 英文摘要………………………………………………………………………………5 緒論...................……………………………………………………………………….9 實驗材料與方法……………….…………………………………………………….10 第一章 天然物在人類荷爾蒙不依賴型前列腺癌細胞的抗癌機轉:氧化性壓力、鈣離子失衡與DNA損傷之角色探討………………………………………….…..23 背景……………………………………………………………………………..24 第一節 Costunolid在人類荷爾蒙不依賴型前列腺癌細胞經由調控細胞核內 鈣離子與造成DNA損傷達成細胞死亡之機轉探討………………………..31 實驗結果…………………………………………………………………..……32 討論與結論…………………………………….……………………………….35 第二節 Moniliformediquinone在人類荷爾蒙不依賴型前列腺癌細胞藉由減 少細胞內glutathione達成抗癌活性之機轉探討……….……………….……39 實驗結果……………………………………………………………………..…40 討論與結論………………………………….……………………………….…43 附圖…………………………………………………………………………..…46 圖…………………………………………………………………………….....48 表…………………………………………………………………………….…66 第二章 EJMC30 在人類荷爾蒙不依賴型前列腺癌細胞經由LKB1-AMPK-mTOR途徑引發細胞週期停滯………………………………………….………………….67 背景……………………………………………………………………….……68 實驗結果…………………………………………………………………….…71 討論與結論………………………………….…………………………………73 附圖…………………………………………………………………………...76 圖………………………………………………………………………….…..77 第三章 Rottlerin促使前列腺癌細胞對camptothecin感受度增加的機轉探討: 經 由與PKCδ無關的途徑來增加及穩定topoisomerase-DNA斷裂複合物...........85 背景…………………………………………………………………………...86 實驗結果……………………………………………………………………...89 討論與結論………………………………………….………………………..93 附圖…………………………………………………………………………...96 圖……………………………………………………………………………...97 表……………………………………………………………………………...103 第四章 總結與展望……………………………………………………………...105 圖………………………………………………………………………………107 著作………………………………………………………………………………..108 參考文獻…………………………………………………………………………..109 | |
dc.language.iso | zh-TW | |
dc.title | 天然物及合成化合物在人類荷爾蒙不依賴型前列腺癌
的抗癌機轉探討 | zh_TW |
dc.title | Investigation of anticancer mechanisms of natural products
and synthetic compounds in human hormone-refractory prostate cancers | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 黃聰龍,許麗卿,楊家榮,蕭哲志 | |
dc.subject.keyword | 前列腺癌,抗癌機轉, | zh_TW |
dc.subject.keyword | prostate cancer,anticancer mechanism, | en |
dc.relation.page | 122 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-07-24 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 5.49 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。